BioLine RX
BioLine RX
BLRX
NASDAQ
0.65
USD
225.00%
About
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 202.0K |
| Three Month Average Volume | 6.4M |
| High Low | |
| Fifty-Two Week High | 2.53 USD |
| Fifty-Two Week Low | 0.51 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 03 Jul 2024 |
| Price and Volume | |
| Current Price | 0.6469 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -9.55% |
| Thirteen Week Relative Price Change | -18.93% |
| Twenty-Six Week Relative Price Change | -55.76% |
| Fifty-Two Week Relative Price Change | -70.50% |
| Year-to-Date Relative Price Change | -65.21% |
| Price Change | |
| One Day Price Change | 0.95% |
| Thirteen Week Price Change | -13.24% |
| Twenty-Six Week Price Change | -51.36% |
| Five Day Price Change | -12.02% |
| Fifty-Two Week Price Change | -63.03% |
| Year-to-Date Price Change | -58.80% |
| Month-to-Date Price Change | -17.63% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.18254 USD |
| Book Value Per Share (Most Recent Quarter) | 0.18029 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.02252 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.0156 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.55168 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.07474 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.17408 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.9438 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.76275 USD |
| Normalized (Last Fiscal Year) | -0.8394 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.9438 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.76275 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.9438 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.76275 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.59352 USD |
| Cash Per Share (Most Recent Quarter) | 0.38892 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.92924 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.70389 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.43168 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,481 |
| Cash Flow Revenue (Trailing Twelve Months) | -248 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -421.69% |
| Pretax Margin (Last Fiscal Year) | -1,262.79% |
| Pretax Margin (5 Year) | -3,501.79% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 23.08% |
| Gross Margin (Trailing Twelve Months) | 55.84% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,035.29% |
| Operating Margin (Trailing Twelve Months) | -391.76% |
| Operating Margin (5 Year) | -3,222.21% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,262.79% |
| Net Profit Margin (Trailing Twelve Months) | -421.69% |
| Net Profit Margin (5 Year) | -3,501.79% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -49.19% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -50.72% |
| Total Debt (5 Year) | 5.83% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 95.14% |
| EPS Change (Trailing Twelve Months) | -30.32% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -16,859,000 |
| Net Debt (Last Fiscal Year) | -31,403,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 12 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 4 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 60 |
| Long Term Debt to Equity (Most Recent Quarter) | 55 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -22,905,000 |
| Free Cash Flow (Trailing Twelve Months) | -28,901,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -566 |
| Net Interest Coverage (Trailing Twelve Months) | -519 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 88 |
| Total Debt to Equity (Most Recent Quarter) | 87 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -86.40% |
| Return on Assets (Trailing Twelve Months) | -81.75% |
| Return on Assets (5 Year) | -52.74% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -189.23% |
| Return on Equity (Trailing Twelve Months) | -188.40% |
| Return on Equity (5 Year) | -83.37% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -122.73% |
| Return on Investment (Trailing Twelve Months) | -127.94% |
| Return on Investment (5 Year) | -65.43% |